Phase-I trial of HSPCAR30 therapy shows 100% response and 50% remission in CD30+ lymphoma patients with no major side effects ...

To diagnose non-Hodgkin‘s lymphoma, doctors may use blood tests, biopsies, and imaging scans such as CT scans or MRIs. These tests help doctors confirm the presence of the disease and plan the ...

Check out our weekly list of new fundraisers from Lend A Hand Up, a nonprofit crowdfunding site supporting families in Cass, ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...

Hodgkin lymphoma and other CD30+ lymphomas have posed a major challenge to the medical community, especially in relapsed or refractory cases where conventional treatments have so far shown limited ...

While Hodgkin lymphoma generally affects younger people, other lymphomas affect older adults and the older the person, the more prone they are. Actors Jane Fonda, Jeff Bridges, and most recently ...

Overall cancer mortality rates decreased for men, women and children in the U.S. between 2018 and 2022, according to the National Cancer Institute’s “Annual Report to the Nation on the Status of ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

The HD21 trial enrolled patients with advanced Hodgkin lymphoma, including those with Stage IIb large mediastinal mass or extranodal lesions. Participants received two cycles of either escalated ...